WHO Chemical Risk Assessment Workshop on new and emerging risks to human health from chemicals RIVM is hosting an international workshop on new and emerging risks from chemicals on 20 and 21 February 2019.
Possible health risks due to exposure to chromium-6 at tROM project Tilburg Research by RIVM shows that the participants in the so-called tROM project, their supervisors and other people involved may have been exposed to chromium-6.
Kick off European Project VITAL: Vaccines and InfecTious diseases in the Ageing popuLation Recently, the EU-sponsored Vaccines and InfecTious diseases in the Ageing popuLation (VITAL) project was launched.
Less STI tests in The Netherlands The number of people who were tested for a Sexually Transmitted Infection (STI) at a Dutch STI clinic has dropped for the first time in years.
RIVM and Chinese monitoring center for oceans exploring collaboration Knowledge development in China is valuable for addressing environmental issues in Europe, and vice versa.
Technical files of silicone breast implants show shortcomings For medical devices such as breast implants, manufacturers are obliged to compile a ‘technical file’ based on which market authorization of the product will be decided.
Annual report 2015 RIVM online In our annual report, we look back at compelling RIVM projects and research in 2015.
Less air pollution from traffic and industry but increased contribution from agriculture International air policy has shown good results in Europe: in the past 35 years the air has become cleaner. Nevertheless air pollution is still an important cause of premature death.
Early detection of work-related health risks in Europe At European level, different methods are used to identify substances and processes that may cause cancer as early as possible, the so-called early warning systems.
Burden of disease and societal costs of work-related cancer in the European Union Yearly approximately 122,600 people in the EU are diagnosed with cancer, caused by past exposure to carcinogenic substances at work.